Gland Pharma delivered solid Q1 FY27 results with revenue jumping 20% YoY to ₹1,800.3 Cr and Net Profit soaring 47% YoY to ₹317 Cr.

Adjusted EBITDA margin improved to 28%. Both CDMO and B2B segments showed robust growth, contributing almost equally to revenue.

The US market, a major revenue driver, grew 32% thanks to new launches like Dalbavancin & Multi-Vitamin and higher volumes of existing products.

Europe also expanded 20% YoY.

The company is investing ₹77.2 Cr (4% of revenue) in R&D, launching 4 new US molecules and securing 7 ANDA approvals this quarter.

Future growth is centered on complex injectables, a strong pipeline of Ready-to-Use (RTU) bags addressing a $644 million US market opportunity, and strategic partnerships.

A recent CDMO tie-up with a global pharma company is targeting USD 90-100 million in annual revenue from 2029, with co-developed products expected to commercialize from FY28.